EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom

Monica Hernandez Alava, Allan Wailoo, Sabine Grimm, Stephen Pudney, Manuel Gomes, Zia Sadique, David Meads, John O'Dwyer, Garry Barton, Lisa Irvine

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)49-56
Number of pages8
JournalValue in Health
Volume21
Issue number1
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • cost effectiveness
  • EQ-5D
  • health utility
  • RANDOMIZED CONTROLLED-TRIAL
  • EARLY RHEUMATOID-ARTHRITIS
  • VALUE SET
  • HEALTH STATES
  • DISEASE
  • GLUCOCORTICOIDS
  • DRUGS

Cite this

Alava, M. H., Wailoo, A., Grimm, S., Pudney, S., Gomes, M., Sadique, Z., ... Irvine, L. (2018). EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom. Value in Health, 21(1), 49-56. https://doi.org/10.1016/j.jval.2017.09.004
Alava, Monica Hernandez ; Wailoo, Allan ; Grimm, Sabine ; Pudney, Stephen ; Gomes, Manuel ; Sadique, Zia ; Meads, David ; O'Dwyer, John ; Barton, Garry ; Irvine, Lisa. / EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom. In: Value in Health. 2018 ; Vol. 21, No. 1. pp. 49-56.
@article{0ed7411bf7344ce9ac832b58bbbecf73,
title = "EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom",
keywords = "cost effectiveness, EQ-5D, health utility, RANDOMIZED CONTROLLED-TRIAL, EARLY RHEUMATOID-ARTHRITIS, VALUE SET, HEALTH STATES, DISEASE, GLUCOCORTICOIDS, DRUGS",
author = "Alava, {Monica Hernandez} and Allan Wailoo and Sabine Grimm and Stephen Pudney and Manuel Gomes and Zia Sadique and David Meads and John O'Dwyer and Garry Barton and Lisa Irvine",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jval.2017.09.004",
language = "English",
volume = "21",
pages = "49--56",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier Science",
number = "1",

}

Alava, MH, Wailoo, A, Grimm, S, Pudney, S, Gomes, M, Sadique, Z, Meads, D, O'Dwyer, J, Barton, G & Irvine, L 2018, 'EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom', Value in Health, vol. 21, no. 1, pp. 49-56. https://doi.org/10.1016/j.jval.2017.09.004

EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom. / Alava, Monica Hernandez; Wailoo, Allan; Grimm, Sabine; Pudney, Stephen; Gomes, Manuel; Sadique, Zia; Meads, David; O'Dwyer, John; Barton, Garry; Irvine, Lisa.

In: Value in Health, Vol. 21, No. 1, 01.01.2018, p. 49-56.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom

AU - Alava, Monica Hernandez

AU - Wailoo, Allan

AU - Grimm, Sabine

AU - Pudney, Stephen

AU - Gomes, Manuel

AU - Sadique, Zia

AU - Meads, David

AU - O'Dwyer, John

AU - Barton, Garry

AU - Irvine, Lisa

PY - 2018/1/1

Y1 - 2018/1/1

KW - cost effectiveness

KW - EQ-5D

KW - health utility

KW - RANDOMIZED CONTROLLED-TRIAL

KW - EARLY RHEUMATOID-ARTHRITIS

KW - VALUE SET

KW - HEALTH STATES

KW - DISEASE

KW - GLUCOCORTICOIDS

KW - DRUGS

U2 - 10.1016/j.jval.2017.09.004

DO - 10.1016/j.jval.2017.09.004

M3 - Article

VL - 21

SP - 49

EP - 56

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 1

ER -